P roprotein convertase subtilisin/kexin type 9 (PCSK9) has been recognized for its pivotal role in low-density lipoprotein-cholesterol (LDL-C) metabolism. 1-3 PCSK9 plays a key role in the post-translational regulation 4 of hepatic LDLreceptor (LDL-R) activity, with the binding of PCSK9 to LDL-R promoting receptor degradation and impeding the ability of the liver to remove circulating LDL particles. 5, 6 Because an elevated plasma concentration of LDL-C has been well established as an atherosclerotic risk factor, 7 PCSK9 presents itself as a potential novel predictor of cardiovascular risk and as a target for lipid-lowering therapy.
Results

Baseline Participant Demographics
The study cohort for which PCSK9 data were collected (n=1527) consisted of middle-aged firefighters (mean age, 49.4 years) in good health; this was evidenced by a low 10-year Framingham Risk Score (FRS; 7.9%). Prevalence of metabolic syndrome (MS) among participants was moderate, as was a family history of vascular disease, affecting 21% and 25% of participants, respectively. Only 15% of subjects required cardiovascular medication, with 11% for hypertension, and 8% on statin therapy. Mean LDL-C was 3.29 mmol/L; mean high-density lipoprotein-cholesterol was 1.25 mmol/L; and median high-sensitivity C-reactive protein was found to be 1.26 mg/L ( Table 1 ). Serum PCSK9 concentrations were distributed with a rightward skew and measured as a median concentration of 286 ng/mL (231-355 ng/mL), which seems normal given the study cohort composition. 11
Baseline Vascular Measures
Baseline brachial artery FMD was 8.6±4.0%; nitroglycerinmediated dilation was 15.0% (11.5%-18.9%); cIMT was 0.70 mm (0.60-0.80 mm); and reactive hyperemic VTI was measured as 121±40 cm-all relatively normal values given the age and composition of the study cohort ( Table 2 ).
Relationship of Risk Factors to PCSK9
In univariate models, PCSK9 concentration was significantly correlated (P<0.05) with several traditional risk factors, including age, FRS, MS, fasting glucose, insulin, statin therapy, waist circumference, body mass index (BMI), total cholesterol, LDL-C, and triglycerides. However, multiple regression analysis demonstrated that insulin, BMI, LDL-C, and triglycerides were independent predictors of PCSK9 serum concentrations (Table 3 ). Of these, BMI was inversely associated with PCSK9 (β=−0.0064; P=0.0209).
Cardiovascular Events
Over a mean follow-up period of 7.2±1.7 years, 111 events were recorded in 71 subjects. These events included 21 nonfatal myocardial infarctions and 41 revascularizations (28 percutaneous and 13 coronary bypass surgeries). A small number of cases were cerebrovascular (n=12), with even fewer occurrences of peripheral vascular events (n=1). During the period of follow-up, 27% were undergoing drug therapy for hypertension and 25% were being treated for lipid lowering.
Relationship of PCSK9 to Cardiovascular Events
Analyses conducted using Cox-proportional hazard modeling seemed to show no relationship between PCSK9 concentration and cardiovascular events, with PCSK9 series split along the quintile, quartile, median, 75th percentile, and 90th percentile all possessing P>0.05 in Cox models. Consequently, the possibility of PCSK9 concentrations being associated with cardiovascular events in this study cohort was dismissed, and the continuous PCSK9 data set was used in subsequent proportional hazard analyses. The final Cox model (Table 4) included MS, FRS, and continuous PCSK9, with MS (P=0.02; hazard ratio, 1.85) and FRS (P<0.001; hazard ratio, 1.86) contributing to the likelihood of coronary events. PCSK9 concentration (P=0.195; hazard ratio, 1.16) was not related to the incidence of previously defined cardiovascular events. Kaplan-Meier analyses run with the 75th percentile PCSK9 concentration as the cutoff also failed to show significance between PCSK9 concentrations and the occurrence of cardiovascular events (log-rank P=0.142).
Relationship of PCSK9 to Vascular End Points
Univariate analysis showed significant correlation between cIMT and the majority of tested cardiovascular risk factors ( Table I in the online-only Data Supplement), including FRS, MS, diabetes mellitus, BMI, cholesterols, and high-sensitivity C-reactive protein. Of particular interest, PCSK9 concentration was related to cIMT (β=0.073; P=0.005); however, in backward multiple regression models, PCSK9 concentration was not an independent predictor of cIMT. In a simplified multivariate model (n=1459; R 2 = 0.235), only age and insulin were found to be prognosticators of cIMT (Table II in the online-only Data Supplement). In a separate analysis, FRS was independently associated with cIMT (n=1502; R 2 = 0.170), whereas PCSK9 concentration was not additive to FRS.
In contrast, FMD was only associated with systolic and diastolic blood pressure and the presence of hypertension after univariate analyses, with systolic blood pressure identified as the singular independent predictor of FMD in a multivariate model (n=1512; R 2 = 0.006). PCSK9 concentration was not related to FMD in either univariate or multivariate analyses.
Reactive hyperemic VTI was significantly related to most of the examined risk factors other than smoking status, family history, and PCSK9 concentrations during the course of univariate correlation analyses. Continued linear regression model generation (n=1455; R 2 = 0.170) elucidated the role of age, systolic blood pressure, insulin, BMI, LDL-C, and highsensitivity C-reactive protein as independent predictors of VTI ( Table II in the online-only Data Supplement). In a surrogate model (n=1498; R 2 = 0.134), FRS was independently associated with VTI, whereas yet again, PCSK9 concentration was not an independent predictor.
Discussion
In a large cohort of previously healthy men, the current study demonstrated that PCSK9 was associated with concentrations of LDL-C, triglycerides, and insulin and inversely related to BMI. However, we did not find a consistent association Nonstandard Abbreviations and Acronyms cIMT carotid intima media thickness
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VTI velocity time integral between elevated PCSK9 concentrations and the occurrence of cardiovascular events. Finally, we were unable to demonstrate an independent relationship between PCSK9 concentration and markers of vascular health-the focus of our study. Although PCSK9 concentration was correlated with cIMT in univariate and multivariate models, correction for age rendered the relationship nonsignificant.
Predictors of PCSK9 Concentrations
PCSK9 is thought to increase circulating LDL-C concentrations through the promotion of LDL-R degradation when bound. 5, 6 PCSK9 is tightly regulated by intracellular cholesterol, hormones, and metabolic status. 12, 13 Genetic association studies have found that subjects with loss of function PCSK9 mutations have lower LDL-C concentrations and protection against cardiovascular disease, 3 highlighting the importance of clinical applications of PCSK9 inhibition. Indeed, the therapeutic potential of its antagonism is of particular interest to researchers, with numerous pharmaceutical trials currently underway. 14, 15 Given the importance of PCSK9 as a potential atherogenic risk marker, 3, 16 we examined the clinical parameters associated with its circulating concentrations. We demonstrate that age, FRS, MS, fasting glucose, insulin, statin therapy, waist circumference, BMI, total cholesterol, LDL-C, and triglycerides were correlated with PCSK9 concentration-findings largely reflected in similar large cohort studies. 11, 12, 17, 18 No previous literature exists, which examines the relationship between PCSK9 and FRS and MS. Dubuc et al 18 used multiple stepwise regression to present a simplified predictive model of PCSK9 with total cholesterol, fasting glucose, triglycerides, sex, and age as the significant factors. Similarly, the optimal multivariate model in this study contains insulin, LDL-C, and triglycerides as associates of PCSK9.
Although BMI was also associated with PCSK9 concentration, it is notable that they were inversely correlated; this association was also observed in the study of plasma PCSK9 in children and adolescents by Baass et al, 12 where age, glucose, insulin, and adiponectin were adjusted for. Interestingly, an article examining the relationship between PCSK9 and thyrotropin 19 found that the association between thyrotropin and PCSK9 was disrupted in patients with a BMI ≥30 kg/m 2 . Similarly, resistin was only correlated with PCSK9 concentration in patients with a BMI <35 kg/m 2 . 20 These findings suggest a disruption in PCSK9 concentration in patients with higher adiposity values. Given the mean BMI of the Firefighters and Their Endothelium (FATE) cohort as 28.5±3.6 kg/m 2 , it is possible that the inverse correlation between PCSK9 concentrations and BMI is because of the disruption of the PCSK9 pathway in high BMI subjects. The exact mechanism of this disruption is unknown.
It is not surprising that insulin concentrations are associated because the hormone is thought to induce PCSK9 expression, 13 with a previous study noting that a 10% rise in fasting insulin was associated with a 1% to 2% increase of PCSK9. 12 The connection between insulin and PCSK9 concentration means that the metabolic environment modulates PCSK9 production, with experiments involving mice models showing a drop in circulating PCSK9 concentrations after a 24-hour fasting period. Interestingly, in vitro testing shows that PCSK9 production, as measured by corresponding mRNA levels, is unaffected by blood glucose concentration. It has been proposed that PCSK9 is mediated by an insulin-dependent pathway, with sterol regulatory element-binding protein 1c 13 and sterol regulatory element-binding protein 2 as the mediators. 21 Using mouse models, endogenous PCSK9 has been shown to regulate very low-density lipoprotein receptor concentrations in adipose tissue, serving an important role in fat metabolism. 22 Experiments involving PCSK9 null mice show that a lack of PCSK9 is protective against postprandial triglyceridemia. 23 Moreover, multiple large cohort studies 11, 12, 17, 18 have associated plasma PCSK9 concentration with plasma triglycerides. However, the exact mechanism of PCSK9 influence on triglyceride metabolism is still uncertain.
Table 2. Baseline Vascular Measurements of Firefighters and Their Endothelium Cohort
The biochemical relationship between PCSK9 and LDL-C has been described in detail, with multiple studies finding that PCSK9 concentrations are correlated with LDL-C concentrations. 3, 24, 25 Multiple clinical trials are currently in place, with Blom et al 14 recently publishing the results of their 52-week trial of evolocumab, a monoclonal antibody that inhibits PCSK9. Their findings show that evolocumab significantly reduces LDL-C concentrations in participants with hyperlipidemia, with similar PCSK9 inhibiting drugs presenting an important breakthrough in dyslipidemia treatment and cardiovascular risk mitigation.
PCSK9 and Cardiovascular Events
We were able to compare PCSK9 concentrations with cardiovascular outcomes during a mean follow-up period of 7.2±1.7 years, finding that PCSK9 was not a strong predictor of cardiovascular events. In a 2006 article by Cohen et al, 3 individuals with mutations decreasing PCSK9 function had significantly reduced LDL-C concentrations, resulting in fewer cardiovascular events. Although this association between PCSK9 and events was not replicated in the FATE cohort, this study differs in that it compares PCSK9 concentrations, not the presence of genetic PCSK9 mutants, with the incidence of cardiovascular events. However, these findings were unexpected as PCSK9 was correlated with LDL-C concentrations, which have been repeatedly linked to the occurrence of adverse cardiovascular outcomes. The study may have been underpowered for this secondary end point.
PCSK9 and Vascular Metrics
Endothelial dysfunction is an early step in the pathogenesis of atherosclerotic risk, with measures of endothelial function shown to be surrogates of adverse outcomes. This is the only study we are aware of to report the relationship between PCSK9 and vascular end points.
FMD remains the most used technique in the measurement of endothelial function-FMD assesses conduit vessel function and has been associated with cardiovascular outcomes in some, but not in all previous studies. Although the Multi-Ethnic Study of Atherosclerosis (MESA) was a large cohort study, which found that FMD functioned as an independent predictor of cardiovascular events, the relationship only altered reclassification indices to a minor extent, with a low degree of significance once traditional risk factors were considered. 26 Previous FATE investigations showed that FMD was only related to blood pressure, and that no independent association between FMD and events existed. 10, 27 In the present study, PCSK9 was not related to FMD in either univariate or multivariate analyses. Although FATE was the earliest study to demonstrate that hyperemic velocity, a measure of microvascular function, was independently related to cardiovascular events in a primary prevention population, 10 and despite being significantly correlated with numerous traditional risk factors and C-reactive protein in univariate analyses, VTI was not associated with PCSK9 concentrations in the current analysis.
From these findings, we conclude that there is no relationship between PCSK9 and endothelial function in this cohort. Because PCSK9 is a regulator of LDL, and LDL has been related to endothelial function in multiple studies, it was somewhat surprising that PCSK9 was not identified as a predictor of FMD. In the FATE study, LDL-C was related to FMD but not to hyperemic velocity. Whether this is because of the different mediators involved in conduit and microvascular responses remains uncertain. A 2009 study by Lakoski et al 11 found that differences in plasma PCSK9 concentrations could only explain <8% of the corresponding variation in LDL-C, suggesting that circulating PCSK9 concentrations give a poor representation of overall PCSK9 activity.
Carotid IMT is a measure of subclinical atherosclerosis and functions as a widely accepted surrogate of atherosclerosis risk for research studies. In the previously published FATE study, carotid IMT was related to outcomes independently of FRS; however, cIMT is not widely used as a clinical tool and adds little to the reclassification of participants. In univariate analyses, cIMT was correlated with nearly identical risk factors as VTI. PCSK9 was a significant univariate correlate of cIMT; however, with the addition of age in multivariate models, PCSK9 was no longer significant, leaving only insulin as the other independent predictor of cIMT. The strong relationship between age and carotid thickness is supported by past findings 28 and is expected. Studies involving the Progression of Lesions in the Intima of the Carotid and Coronary Artery Risk Development in Young Adults groups discovered PCSK9 gain-of-function mutants experienced an accelerated progression of IMT thickening when compared with the general population, whereas loss-of-function mutants possessed lower cIMT measurements. 29, 30 These 2 investigations demonstrate a relationship between PCSK9 concentrations and cIMT; however, the study at hand differs from the study by Huang et al 29 and Norata et al 30 in that PCSK9 mutants were not specifically examined. At this time, there are no previous studies comparing PCSK9 concentrations and cIMT.
Limitations
Several important limitations must be given consideration. The cohort is limited to healthy, middle-aged, mainly white men, and is not representative of other populations. Since the baseline data were gathered, techniques have been described, which yield more detailed carotid data than the one used in FATE including the assessment of carotid plaque. 31 Posttranslation modification of PCSK9 is known to affect activity, and novel techniques allowing for the quantification of active and inactive PCSK9 have been recently developed to account for this fact. 32 As the assay used in this study is unable to differentiate between active and inactive PCSK9, the efficacy of PCSK9 as a marker of vascular health should be re-examined using these novel techniques. Although the follow-up for the study was conducted over a long period, there were still a limited number of cardiovascular end points to draw firm conclusions about the relationship with outcomes. Moreover, we cannot exclude the proprotein's relationship with cardiovascular events and vascular function in individuals with gainof-function mutations associated with much higher PCSK9 activity levels. Finally, serum PCSK9 concentrations were used in this investigation; however, circulating PCSK9 concentrations may not be indicative of actual PCSK9 activity. 11
Conclusions
In healthy men, PCSK9 concentration was independently associated with several traditional risk factors. This relationship did not extend further as PCSK9 was not independently related with measures of vascular health, subclinical atherosclerosis, or cardiovascular events. PCSK9, despite being a therapeutic target for LDL-C reduction, is unlikely a biomarker of atherosclerotic risk. However, these findings are only in relation to PCSK9 concentration, and single nucleotide polymorphisms may still have a significant role in the prediction of cardiovascular disease.
The finding that circulating levels of proprotein convertase subtilisin/kexin type 9 were not associated with intermediate or hard vascular end points in the current study does not lessen the importance of this mechanism for treatment. The study was well powered for vascular end points, and no association was found. These end points have been established as surrogate markers of vascular risk and are helpful for clinical research, but have not been widely adopted into clinical practice either. There are also many other examples of mismatch between the efficacy of therapeutic agents and biomarkers including lipoprotein phospholipase A 2 , homocysteine, Lp(a), and high-density lipoprotein to name a few. Thus, the measurement of proprotein convertase subtilisin/kexin type 9 is unlikely to be used as a risk predictor in primary prevention, but the therapeutic value of this pathway is likely to be important in clinical care.
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